U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. HYQVIA
  1. Approved Blood Products

HYQVIA

STN: BL 125402/0
Proper Name: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Tradename: HYQVIA
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Indication:

HYQVIA is an Immune Globulin Infusion 10% (Human) with a Recombinant Human Hyaluronidase (rHuPH20) indicated for the treatment of

  • Primary Immunodeficiency (PI) in adults and pediatric patients two years of age and older.
  • Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Product Information

Supporting Documents

Back to Top